Remove BioTech Remove healthcare technology Remove Strategy
article thumbnail

Wound Care: Emerging HealthTech market to watch in 2025

Lloyd Price

Focus on Chronic Wounds: Chronic wounds, such as diabetic ulcers and pressure ulcers, remain a significant healthcare challenge. The increasing prevalence of these conditions is driving demand for innovative solutions and improved management strategies. Subscribe Today!

article thumbnail

HealthTech M&A Multiples March 2025: Current Trends and Variables driving valuations

Lloyd Price

Big Pharmas looming patent cliffs could drive outlier deals (7-8x or more) for late-stage innovators, especially in biotech-adjacent HealthTech. in 2023 but still higher than the average revenue multiple for all technology companies, which is 3.5x. What are the biggest trends likely to affect healthcare technology multiples in 2025?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

2021HealthTech IPO Rush: 20+ Digital Health companies went public in 2021 but where are they now?

Lloyd Price

Nelson Advisors Healthcare Technology > Mergers, Acquisitions, Growth, Strategy, Investments [link] We work with Healthcare Technology founders, owners and investors to assess whether they should 'Build, Buy, Partner, Invest or Sell' in order to maximise shareholder value and investment returns.

article thumbnail

Doximity - the 'Linkedin for Doctors' is the best performing healthcare stock in 2025

Lloyd Price

These figures highlight its ability to grow profitably, a rarity in healthcare IT, and its dominance in the digital physician market, which it expects to expand 5-7% annually, with Doximity aiming to outpace that. Comparatively, the healthcare sector has lagged in recent years, but 2025 is showing signs of a turnaround.

article thumbnail

Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials

Digital Health Global

As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. We look for similar customer-oriented ethos and patient-centric mindsets in our partnerships,” said Kim Kushner, Chief Business Officer, SSI Strategy. Learn more at koneksahealth.com.

article thumbnail

Koneksa Announces Study with New York Proton Center to Collect Patient-Generated Health Data During Proton Radiotherapy in Lung Cancer

Digital Health Global

About Koneksa Koneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical research and guide decision-making in drug development and market strategy. These adverse events often lead to hospitalizations and treatment interruptions that can reduce treatment efficacy.

article thumbnail

Colin Bower Joins VivoSense as Chief Executive Officer

Digital Health Global

Colin’s track record with global biopharma and biotech partners is extensive and admirable,” added Chris Garabedian, a VivoSense Board Member. “He He has consistently worked to improve the speed, safety, and cost-effectiveness of clinical trials through the adoption of new technological solutions. We are on Twitter.